Advanced search
Publication Cover
Acta Oncologica Volume 51, 2012 - Issue 1
Journal homepage
1,955
Views
49
CrossRef citations to date
0
Altmetric
Research Article

Minor changes in effective half-life during fractionated 177Lu-Octreotate therapy

Ulrike GarskeDepartment of Radiology, Oncology and Radiation Science, Department of Medical Sciences, Section of Nuclear Medicine, Uppsala University Hospital, Uppsala, Sweden
,
Mattias SandströmDepartment of Oncology, Radiology and Radiation Science, Section of Medical Physics. Uppsala University Hospital, Uppsala, SwedenCorrespondence[email protected]
,
Silvia JohanssonDepartment of Radiology, Oncology and Radiation Science, Section of Oncology and Nuclear Medicine, Uppsala University Hospital, Uppsala, Sweden
,
Anders SundinDepartment of Radiology, Karolinska Institute, Stockholm and Uppsala University Hospital, Sweden
,
Dan GranbergDepartment of Medical Sciences, Section of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden
,
Barbro ErikssonDepartment of Medical Sciences, Section of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden
&
Hans LundqvistUppsala University, Department of Oncology, Radiology and Radiation Science, Rudbeck Laboratory, Uppsala, Sweden
 show all
Pages 86-96 | Received 10 Jun 2011, Accepted 24 Aug 2011, Published online: 03 Oct 2011

Citations (49)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Mattias Sandström, Ulrike Garske-Román, Silvia Johansson, Dan Granberg, Anders Sundin & Nanette Freedman. (2018) Kidney dosimetry during 177Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance. Acta Oncologica 57:4, pages 516-521.
Read now
Jorma Heikkonen, Hanna Mäenpää, Eero Hippeläinen, Vappu Reijonen & Mikko Tenhunen. (2016) Effect of calculation method on kidney dosimetry in 177Lu-octreotate treatment. Acta Oncologica 55:9-10, pages 1069-1076.
Read now

Articles from other publishers (47)

Rudolf A. Werner, Seval Beykan, Takahiro Higuchi, Katharina Lückerath, Alexander Weich, Michael Scheurlen, Christina Bluemel, Ken Herrmann, Andreas K. Buck, Michael Lassmann, Constantin Lapa & Heribert Hänscheid. (2016) The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathy. Oncotarget 7:27, pages 41233-41241.
Crossref
Amit Nautiyal, Sofia Michopoulou & Matt Guy. (2023) Dosimetry in Lu-177-DOTATATE peptide receptor radionuclide therapy: a systematic review. Clinical and Translational Imaging.
Crossref
Siju C. George & E. James Jebaseelan Samuel. (2023) Developments in 177Lu-based radiopharmaceutical therapy and dosimetry. Frontiers in Chemistry 11.
Crossref
Alexandre Chicheportiche, Moshe Sason, Mahmoud Zidan, Jeremy Godefroy, Yodphat Krausz, David J. Gross, Simona Grozinsky-Glasberg & Simona Ben-Haim. (2023) Impact of Single-Time-Point Estimates of 177 Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles . Journal of Nuclear Medicine, pages jnumed.122.264923.
Crossref
Ulrika Jahn, Ulrike Garske-Román, Mattias Sandström, Mark Lubberink & Anders Sundin. (2023) Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression. EJNMMI Research 13:1.
Crossref
Nathaly Barbosa Parada, Franklin Niño Duarte, Lorena Sandoval Castillo & Erika Xiomara Cely Segura. (2022) Protección radiológica en terapias con 177Lu DOTATOC: tiempo de aislamiento, estimaciones de dosis a personas representativas y recomendaciones al paciente. Revista Colombiana de Cancerología 26:4, pages 432-41.
Crossref
Oscar Ardenfors, Joachim N. Nilsson, Daniel Thor & Cecilia Hindorf. (2022) Simplified dosimetry for kidneys and tumors in 177Lu-labeled peptide receptor radionuclide therapy. EJNMMI Physics 9:1.
Crossref
Javian C. Malcolm, Nadia Falzone, Jennifer E. Gains, Matthew D. Aldridge, David Mirando, Boon Q. Lee, Mark N. Gaze & Katherine A. Vallis. (2022) Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [177Lu]Lu-DOTATATE. EJNMMI Physics 9:1.
Crossref
Laure Vergnaud, Anne-Laure Giraudet, Aurélie Moreau, Julien Salvadori, Alessio Imperiale, Thomas Baudier, Jean-Noël Badel & David Sarrut. (2022) Patient-specific dosimetry adapted to variable number of SPECT/CT time-points per cycle for $$^{177}$$Lu-DOTATATE therapy. EJNMMI Physics 9:1.
Crossref
Katarina Sjögreen Gleisner, Nicolas Chouin, Pablo Minguez Gabina, Francesco Cicone, Silvano Gnesin, Caroline Stokke, Mark Konijnenberg, Marta Cremonesi, Frederik A. Verburg, Peter Bernhardt, Uta Eberlein & Jonathan Gear. (2022) EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. European Journal of Nuclear Medicine and Molecular Imaging 49:6, pages 1778-1809.
Crossref
John Kennedy, Alexandre Chicheportiche & Zohar Keidar. (2022) Quantitative SPECT/CT for Dosimetry of Peptide Receptor Radionuclide Therapy. Seminars in Nuclear Medicine 52:2, pages 229-242.
Crossref
Courtney Lawhn-Heath, Thomas A Hope, Juana Martinez, Edward K Fung, Jaehoon Shin, Youngho Seo & Robert R Flavell. (2022) Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose. The Lancet Oncology 23:2, pages e75-e87.
Crossref
Johan Gustafsson & Jan Taprogge. (2022) Theoretical aspects on the use of single-time-point dosimetry for radionuclide therapy. Physics in Medicine & Biology 67:2, pages 025003.
Crossref
Cinzia Pettinato, Elisa Richetta & Marta Cremonesi. 2022. Nuclear Medicine and Molecular Imaging. Nuclear Medicine and Molecular Imaging 307 315 .
Neeta Pandit-Taskar, Amir Iravani, Dan Lee, Heather Jacene, Dan Pryma, Thomas Hope, Babak Saboury, Jacek Capala & Richard L. Wahl. (2021) Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice. Journal of Nuclear Medicine 62:Supplement 3, pages 60S-72S.
Crossref
Peter Frøhlich Staanum, Anders Floor Frellsen, Marie Louise Olesen, Peter Iversen & Anne Kirstine Arveschoug. (2021) Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates. EJNMMI Physics 8:1.
Crossref
Alexandre Chicheportiche, Moshe Sason, Jeremy Godefroy, Yodphat Krausz, Mahmoud Zidan, Kira Oleinikov, Amichay Meirovitz, David J. Gross, Simona Grozinsky-Glasberg & Simona Ben-Haim. (2021) Simple model for estimation of absorbed dose by organs and tumors after PRRT from a single SPECT/CT study. EJNMMI Physics 8:1.
Crossref
Jens Kurth, Martin Heuschkel, Alexander Tonn, Anna Schildt, Oliver W. Hakenberg, Bernd J. Krause & Sarah M. Schwarzenböck. (2021) Streamlined Schemes for Dosimetry of 177Lu-Labeled PSMA Targeting Radioligands in Therapy of Prostate Cancer. Cancers 13:15, pages 3884.
Crossref
Yuya Sekikawa, Keita Funada, Go Akamatsu, Kazuhiko Himuro, Akihiko Takahashi, Shingo Baba & Masayuki Sasaki. (2021) Monte Carlo simulation of the acquisition conditions for 177Lu molecular imaging of hepatic tumors. Annals of Nuclear Medicine 35:7, pages 823-833.
Crossref
T. Monserrat Fuertes, F.M. González García, M.Á. Peinado Montes, M.L. Domínguez Grande, N. Martín Fernández, A. Gómez de Iturriaga Piña & P. Mínguez Gabiña. (2021) Description of the methodology for dosimetric quantification in treatments with 177Lu-DOTATATE. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 40:3, pages 167-178.
Crossref
T. Monserrat Fuertes, F.M. González García, M.Á. Peinado Montes, M.L. Domínguez Grande, N. Martín Fernández, A. Gómez de Iturriaga Piña & P. Mínguez Gabiña. (2021) Descripción de la metodología para la cuantificación dosimétrica en tratamientos con 177Lu-DOTATATE. Revista Española de Medicina Nuclear e Imagen Molecular 40:3, pages 167-178.
Crossref
Ulrika Jahn, Ezgi Ilan, Mattias Sandström, Mark Lubberink, Ulrike Garske-Román & Anders Sundin. (2021) Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms. Cancers 13:5, pages 962.
Crossref
Virginia Liberini, Osvaldo Rampado, Elena Gallio, Bruno De Santi, Francesco Ceci, Beatrice Dionisi, Philippe Thuillier, Libero Ciuffreda, Alessandro Piovesan, Federica Fioroni, Annibale Versari, Filippo Molinari & Désirée Deandreis. (2021) 68Ga-DOTATOC PET/CT-Based Radiomic Analysis and PRRT Outcome: A Preliminary Evaluation Based on an Exploratory Radiomic Analysis on Two Patients. Frontiers in Medicine 7.
Crossref
Allison J Craig, Bruno Rojas, Jill L Wevrett, Elaine Hamer, Andrew Fenwick & Rebecca Gregory. (2020) IPEM topical report: current molecular radiotherapy service provision and guidance on the implications of setting up a dosimetry service. Physics in Medicine & Biology 65:24, pages 245038.
Crossref
Alexandre Chicheportiche, Simona Ben-Haim, Simona Grozinsky-Glasberg, Kira Oleinikov, Amichay Meirovitz, David J. Gross & Jeremy Godefroy. (2020) Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management. EJNMMI Physics 7:1.
Crossref
Mattias Sandström, Nanette Freedman, Katarzyna Fröss-Baron, Tanweera Kahn & Anders Sundin. (2020) Kidney dosimetry in 777 patients during 177Lu-DOTATATE therapy: aspects on extrapolations and measurement time points. EJNMMI Physics 7:1.
Crossref
Nanette Freedman, Mattias Sandström, Jonathan Kuten, Natan Shtraus, Inna Ospovat, Albert Schlocker & Einat Even-Sapir. (2020) Personalized radiation dosimetry for PRRT—how many scans are really required?. EJNMMI Physics 7:1.
Crossref
Ashutosh Dash, Tapas Das & Furn F. Russ Knapp. (2020) Targeted Radionuclide Therapy of Painful Bone Metastases: Past Developments, Current Status, Recent Advances and Future Directions. Current Medicinal Chemistry 27:19, pages 3187-3249.
Crossref
Ulrika Jahn, Ezgi Ilan, Mattias Sandström, Ulrike Garske-Román, Mark Lubberink & Anders Sundin. (2020) <sup>177</sup>Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors. Neuroendocrinology 110:7-8, pages 662-670.
Crossref
S. Rudisile, A. Gosewisch, V. Wenter, M. Unterrainer, G. Böning, F. J. Gildehaus, W. P. Fendler, C. J. Auernhammer, C. Spitzweg, P. Bartenstein, A. Todica & H. Ilhan. (2019) Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival. BMC Cancer 19:1.
Crossref
Sabine Maurer, Peter Herhaus, Romina Lippenmeyer, Heribert Hänscheid, Malte Kircher, Andreas Schirbel, H. Carlo Maurer, Andreas K. Buck, Hans-Jürgen Wester, Hermann Einsele, Götz-Ulrich Grigoleit, Ulrich Keller & Constantin Lapa. (2019) Side Effects of CXC-Chemokine Receptor 4–Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation. Journal of Nuclear Medicine 60:10, pages 1399-1405.
Crossref
Wei Zhao, Pedro Luis Esquinas, Andrea Frezza, Xinchi Hou, Jean-Mathieu Beauregard & Anna Celler. (2019) Accuracy of kidney dosimetry performed using simplified time activity curve modelling methods: a 177 Lu-DOTATATE patient study . Physics in Medicine & Biology 64:17, pages 175006.
Crossref
Alexandre Chicheportiche, Simona Grozinsky-Glasberg, David J. Gross, Yodphat Krausz, Asher Salmon, Amichay Meirovitz, Nanette Freedman & Jeremy Godefroy. (2018) Predictive power of the post-treatment scans after the initial or first two courses of [177Lu]-DOTA-TATE. EJNMMI Physics 5:1.
Crossref
Kathy P. Willowson, Enid Eslick, Hyunju Ryu, Aurora Poon, Elizabeth J. Bernard & Dale L. Bailey. (2018) Feasibility and accuracy of single time point imaging for renal dosimetry following 177Lu-DOTATATE (‘Lutate’) therapy. EJNMMI Physics 5:1.
Crossref
Alexandre Chicheportiche, Faozi Artoul, Arnon Schwartz, Simona Grozinsky-Glasberg, Amichay Meirovitz, David J. Gross & Jeremy Godefroy. (2018) Reducing the number of CTs performed to monitor personalized dosimetry during peptide receptor radionuclide therapy (PRRT). EJNMMI Physics 5:1.
Crossref
Ulrike Garske-Román, Mattias Sandström, Katarzyna Fröss Baron, Lars Lundin, Per Hellman, Staffan Welin, Silvia Johansson, Tanweera Khan, Hans Lundqvist, Barbro Eriksson, Anders Sundin & Dan Granberg. (2018) Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. European Journal of Nuclear Medicine and Molecular Imaging 45:6, pages 970-988.
Crossref
Heribert Hänscheid, Constantin Lapa, Andreas K. Buck, Michael Lassmann & Rudolf A. Werner. (2018) Dose Mapping After Endoradiotherapy with 177 Lu-DOTATATE/DOTATOC by a Single Measurement After 4 Days . Journal of Nuclear Medicine 59:1, pages 75-81.
Crossref
Michela Del Prete, François-Alexandre Buteau & Jean-Mathieu Beauregard. (2017) Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study. European Journal of Nuclear Medicine and Molecular Imaging 44:9, pages 1490-1500.
Crossref
Shozo Okamoto, Anne Thieme, Jakob Allmann, Calogero D’Alessandria, Tobias Maurer, Margitta Retz, Robert Tauber, Matthias M. Heck, Hans-Juergen Wester, Nagara Tamaki, Wolfgang P. Fendler, Ken Herrmann, Christian H. Pfob, Klemens Scheidhauer, Markus Schwaiger, Sibylle Ziegler & Matthias Eiber. (2017) Radiation Dosimetry for 177 Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions . Journal of Nuclear Medicine 58:3, pages 445-450.
Crossref
Heribert Hänscheid, Constantin Lapa, Andreas Buck, Michael Lassmann & Rudolf Werner. (2018) Absorbed dose estimates from a single measurement one to three days after the administration of 177Lu-DOTATATE/-TOC. Nuklearmedizin 56:06, pages 219-224.
Crossref
Michael Ljungberg, Anna Celler, Mark W. Konijnenberg, Keith F. Eckerman, Yuni K. Dewaraja & Katarina Sjögreen-Gleisner. (2016) MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177 Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy . Journal of Nuclear Medicine 57:1, pages 151-162.
Crossref
Andreas Delker, Wolfgang Peter Fendler, Clemens Kratochwil, Anika Brunegraf, Astrid Gosewisch, Franz Josef Gildehaus, Stefan Tritschler, Christian Georg Stief, Klaus Kopka, Uwe Haberkorn, Peter Bartenstein & Guido Böning. (2015) Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 43:1, pages 42-51.
Crossref
Johanna Svensson, Gertrud Berg, Bo Wängberg, Maria Larsson, Eva Forssell-Aronsson & Peter Bernhardt. (2015) Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment. European Journal of Nuclear Medicine and Molecular Imaging 42:6, pages 947-955.
Crossref
Ezgi Ilan, Mattias Sandström, Cecilia Wassberg, Anders Sundin, Ulrike Garske–Román, Barbro Eriksson, Dan Granberg & Mark Lubberink. (2015) Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177 Lu-DOTATATE . Journal of Nuclear Medicine 56:2, pages 177-182.
Crossref
Run-Sheng Guo, Pei-Dong Shi, Jie Zhou & Yue-Yu Chen. (2013) Somatostatin Receptors 3, 4 and 5 Play Important Roles in Gallbladder Cancer. Asian Pacific Journal of Cancer Prevention 14:7, pages 4071-4075.
Crossref
S. Ezziddin, K. Reichmann, C. Yong-Hing, M. Damm, J. Risse, H. Ahmadzadehfar, T. Logvinski, S. Guhlke, H.-J. Biersack & A. Sabet. (2018) Early prediction of tumour response to PRRT. Nuklearmedizin 52:05, pages 170-177.
Crossref
Mattias Sandström, Ulrike Garske-Román, Dan Granberg, Silvia Johansson, Charles Widström, Barbro Eriksson, Anders Sundin, Hans Lundqvist & Mark Lubberink. (2013) Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing 177 Lu-DOTA-Octreotate Treatment . Journal of Nuclear Medicine 54:1, pages 33-41.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.